Insider filings this month reveal a sharp split between bold buyers and aggressive sellers.
The biggest buy comes from SMMT. Summit Therapeutics Chairman and CEO Robert Duggan filed a $50M purchase on June 12 — snapping up 3.81 million shares at $13.12 each. That's 0.74% of the company in a single trade. President and CEO Mahkam Zanganeh also filed a $1.46M buy earlier in June. Two C-suite executives buying simultaneously is a strong signal of internal confidence.
On the sell side, AMAT dominates. Applied Materials CEO Gary Dickerson filed over $49M in sales across 11 trades on June 15–16. CTO Omkaram Nalamasu added another $20.8M. The board chairman chipped in $5.5M more. Total AMAT insider selling topped $100M in two days of filings.
AGX told a similar story. Argan's subsidiary chairman filed a $32M sale on June 12. Its own CEO filed a $6.5M sale three days later.
DVA CEO Javier Rodriguez filed $14.5M in sales across two DaVita trades filed June 17. The company's Chief Legal Officer also sold $1.9M the same week.
The contrast is stark. SMMT insiders are buying at depressed prices. Tech and healthcare executives are locking in gains near highs.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
